Trial Profile
A randomized, double-blind, crossover study comparing the pharmacodynamic response in subjects with acute coronary syndrome receiving 14 days 10-mg MD prasugrel vs 14 days 150-mg MD [maintenance dose] clopidogrel after using a 900-mg LD [loading dose] of clopidogrel to reduce ongoing platelet activation.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary) ; Clopidogrel
- Indications Acute coronary syndromes; Embolism and thrombosis
- Focus Pharmacodynamics
- Acronyms ACAPULCO
- Sponsors Eli Lilly and Company
- 01 Jan 2010 Results published in Thrombosis and Haemostasis.
- 03 Nov 2009 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.
- 03 Nov 2009 Actual patient number (56) added as reported by ClinicalTrials.gov.